Is Inspire Medical Systems (INSP) Fully Priced As New CPT Codes Lift Sentiment?

Inspire Medical Systems (INSP) drew investor attention after the American Medical Association approved new Category I CPT codes that specifically cover the Inspire V system. These codes are scheduled to take effect in January 2028.

Despite the CPT code win grabbing headlines, Inspire Medical Systems’ share price tells a mixed story, with a 49.03% 3 month share price return and 10.94% 1 month share price return contrasting with a year to date share price decline of 24.17% and a 3 year total shareholder return decline of 60.87%. This suggests that recent momentum is building off a much weaker long run base.

Scan beyond Inspire Medical Systems to see how other healthcare specialists in similar territory are priced and moving using our hand picked 35 healthcare AI stocks.

Bulls see the recent CPT code approval as validation of Inspire Medical Systems’ sleep apnea solution, while bears point to long term share price damage. Which side do the current valuation markers lean toward?

Most Popular Narrative: 16% Overvalued

Against the last close of $69.97, the most followed narrative’s fair value of $60.40 prices Inspire Medical Systems as materially richer than its modeled fundamentals. This keeps the focus squarely on whether future earnings can meet a higher bar set by today’s share price.

The analysts have a consensus price target of $60.4 for Inspire Medical Systems based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $85.0, and the most bearish reporting a price target of just $40.0.

See why 9 investors see Inspire Medical Systems as 16% overvalued.

Result: Fair Value of $60.40 (OVERVALUED)

Still, the narrative can unravel if coding and reimbursement setbacks linger, or if execution issues around Inspire V keep procedure volumes under pressure for longer than expected.

Find out about the key risks to this Inspire Medical Systems narrative.

Another View: Inspire Medical Systems Through The Earnings Lens

The analyst narrative pegs Inspire Medical Systems at 16% above its $60.40 fair value, yet the current P/E ratio tells a very different story. INSP trades at 15x earnings, while peers average 34.7x and the fair ratio for the stock sits at 20.3x. That gap frames INSP as cheaper than both the sector and its own fair ratio. This raises a question: is the crowd leaning too hard on the consensus target and overlooking what current earnings multiples suggest about risk and opportunity?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals around Inspire Medical Systems can feel confusing, so weigh that debate against the actual risk and reward data, and build your own stance quickly with a closer look at 3 key rewards and 1 important warning sign.

Looking for more Inspire Medical Systems investment ideas?

Round out your view on Inspire Medical Systems by lining it up against other opportunities, so you can spot whether this stock truly earns a place in your portfolio.

Scan other potential opportunities quickly so you do not miss stocks that better fit your goals, risk comfort, and timeline.

• Target steady compounding and fewer unpleasant surprises by checking resilient candidates in our 31 resilient stocks with low risk scores.
• Hunt for quality at a price that looks more forgiving by using the 19 high quality undiscovered gems before attention crowds into the same ideas.
• Prioritise financial strength and staying power by sorting through companies in the list of solid balance sheet and fundamentals (26 results) while the market focus remains narrow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com